Treatment of liver metastases of colorectal cancer

Velde, C.J.H. van de

doi:10.1093/annonc/mdi702

Cited by 56 publications

(35 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While hepatic resection is the gold standard treatment for colorectal liver metastasis and is a safe procedure [17], approximately 60-70% of patients undergoing this procedure experience disease recurrence, often in the first 12-18 postoperative months [18]. Of these patients, one-third will have recurrent metastases restricted to the liver.…”

Section: Discussionmentioning

confidence: 99%

Downregulation of osteoprotegerin expression in metastatic colorectal carcinoma predicts recurrent metastasis and poor prognosis

Moon

Kim

et al. 2016

Oncotarget

View full text Add to dashboard Cite

We recently reported the downregulation of osteoprotegerin expression in primary colorectal carcinoma and its significant association with aggressive oncogenic behavior, which suggest that this process contributes to colorectal carcinoma development and progression. In this study, we used immunohistochemical staining to evaluate osteoprotegerin expression in 81 colorectal liver metastasis tissue samples and investigated its possible association with the clinicopathological characteristics and outcomes of patients with colorectal liver metastasis. These tissues exhibited significantly reduced expression of osteoprotegerin compared to primary colorectal carcinomas and normal colorectal mucosa. This reduced expression was significantly associated with the extent of colorectal liver metastasis, including multiplicity of metastatic tumors, involvement of the bilateral hepatic lobes, and higher histological grade. In addition, reduced osteoprotegerin expression was an independent significant predictor of recurrent liver metastasis and prognostic factor for reduced patient survival. These findings suggest that osteoprotegerin expression may be a novel predictor of recurrent liver metastasis and a prognostic biomarker in patients with colorectal liver metastasis. Patients harboring colorectal liver metastasis with reduced osteoprotegerin expression should be carefully monitored after hepatic resection for colorectal liver metastasis to enable early detection of potentially resectable metastatic recurrences.

show abstract

Section: Discussionmentioning

confidence: 99%

Downregulation of osteoprotegerin expression in metastatic colorectal carcinoma predicts recurrent metastasis and poor prognosis

Moon

Kim

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Sin embargo, el desarrollo de MTS es la principal causa de muerte en este tipo de tumor. Las MTS hepáticas son diagnosticadas en el 10-25% de los pacientes en el momento de la resección del tumor primario y más del 70% desarrollan MTS a lo largo de su evolución (4,5).…”

Section: Discussionunclassified

“…El desarrollo de metástasis (MTS) es la principal causa de muerte, afectando con mayor frecuencia al hígado (4,5).…”

unclassified

Fallo hepático fulminante secundario a infiltración maligna hepática

Barreales

Casís

López

et al. 2007

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

show abstract

“…Although only a 10%-20% of the CRC patients with CLM could undergo a surgical excision of the liver metastasis [13][14][15] , the postoperative 5-year survival rate of the patients achieved 20%-40% [16] . However, it was also reported by some authors that the postoperative 5-year survival rate of the patients achieved 58% [2] .…”

Section: Relationship Between Treatment Methods and Prognosis Of The Cmentioning

confidence: 99%

Analysis of prognosis of 122 colorectal cancer patients with concurrent liver metastasis

Luo

Gao

Zhang

et al. 2009

Clin. Oncol. Cancer Res.

View full text Add to dashboard Cite

OBJECTIVETo explore prognostic factors and treatment choices for colorectal cancer (CRC) patients with concurrent liver metastases (CLM). METHODS The data of the 122 CRC patients with CLM, who were treated in our hospital from January 2000 to December 2005, were collected. Overall survival rate of the patients in our group was analyzed using Kaplan-Meier method, and the univariate and multivariate analyses of the 18 factors aff ecting the survival rate, including clinicopathologic factors and treatment methods, were conducted using Log-rank test and Cox regression model (SPSS13.0). RESULTS The median survival time of the 122 patients with CRC was 13 months. The 1, 2, 3 and 5-year survival rate was 52.46%, 24.59%, 12.30% and 3.28%, respectively. Univariate analysis combined with Kaplan-Meier curve revealed that the factors of prognosis included the size of the primary tumor, the levels of differentiation, lymphatic status, cancerous ileus (CI), the number, size and distribution of liver metastases, extrahepatic involvement, the serum CEA level at diagnosis, treatment modality, the extent of primary resection, chemotherapeutic modality and regimen. Multivariate analysis showed that CI, diff erentiation levels, serum CEA value at diagnosis and treatment modality were the independent prognostic factors of CRC patients with CLM. CONCLUSIONFor the CRC patients with CLM, poor differentiation of the tumor and CI, as well as a high CEA level indicate an unfavorable prognosis. Treatment choice is of special significance in treating the CRC patients with CLM, so active radical excision of the primary tumor and liver metastasis is strongly recommended in the CRC patients with hepatic metastasis alone. Interventional chemotherapy has advantages compared with the whole-body chemotherapy via peripheral vein, and the regimen of systemic chemotherapy containing oxaliplatin is preferred.KEY WORDS: colorectal cancer/primary, synchronous liver metastases, prognosis, multivariate analysis, univariate analysis.

show abstract

Treatment of liver metastases of colorectal cancer

Cited by 56 publications

References 66 publications

Downregulation of osteoprotegerin expression in metastatic colorectal carcinoma predicts recurrent metastasis and poor prognosis

Downregulation of osteoprotegerin expression in metastatic colorectal carcinoma predicts recurrent metastasis and poor prognosis

Fallo hepático fulminante secundario a infiltración maligna hepática

Analysis of prognosis of 122 colorectal cancer patients with concurrent liver metastasis

Contact Info

Product

Resources

About